Premium
ORPHENADRINE CITRATE (NORFLEX) FOR THE TREATMENT OF “RESTLESS LEGS” AND RELATED SYNDROMES
Author(s) -
Popkin Roy J.
Publication year - 1971
Publication title -
journal of the american geriatrics society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.992
H-Index - 232
eISSN - 1532-5415
pISSN - 0002-8614
DOI - 10.1111/j.1532-5415.1971.tb01557.x
Subject(s) - medicine , restless legs syndrome , drug , anesthesia , surgery , pharmacology , insomnia
A bstract The purpose of this study was to evaluate the effects of orphenadrine citrate (Norflex) in the syndrome of “restless legs” and nocturnal leg cramps. Of the original 32 patients, 12 were dropped from the study because of gastrointestinal intolerance to the first few doses of the drug or because they were unreliable observers; the symptoms subsided as soon as orphenadrine was discontinued. In the 20 remaining patients the drug was well tolerated; they received it in an oral dosage of 100 mg (occasionally 200 mg) daily for periods ranging from three months to one year. Orphenadrine citrate was found to be an effective therapeutic agent by itself in 16 of the 20 cases, and in combination with other drugs in 4 cases.